New enzyme replacement therapies launched

Patients with two rare inherited metabolic conditions can now benefit from treatment with specific enzyme replacement therapies.

Kanuma (sebelipase alfa) is licensed for use in patients with lysosomal acid lipase deficiency, a condition causing chronic build-up of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissues, leading to multi-organ damage and premature death. 

Further information
View Kanuma drug record
View Strensiq drug record
Manufacturer: Alexion

Strensiq (asfotase alfa) is indicated for the treatment of paediatric-onset hypophosphatasia, a disorder caused by low levels of alkaline phosphatase and characterised by defective bone mineralisation that can lead to bone deformity and destruction, muscle weakness, seizures, respiratory failure and premature death. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Additional tiotropium inhaler available to prescribe

Additional tiotropium inhaler available to prescribe

Acopair is delivered by the dry powder NeumoHaler device.

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...